Novel Cardiovascular Biomarker Secretoneurin Implicated in Arrhythmogenesis

Secretoneurin may play a role in regulating processes in the myocardium, including cardiomyocyte Ca²⁺ handling, and has been implicated in arrhythmogenesis.

Those affected by arrhythmogenic cardiomyopathy may not have any symptoms at all despite having significant abnormalities in the structure of their hearts. If symptoms do occur, the initial presentation is often due to abnormal heart rhythms (arrhythmias) which in arrhythmogenic cardiomyopathy may take the form of palpitations, or blackouts.

An international team of medical scientists led by those at the Haukeland University Hospital (Bergen, Norway) included 30 healthy volunteers in a study that examined the within subject variation (CVI), between subject variation (CVG), reference change values (RCV) and index of individuality (II) of secretoneurin. Inclusion criteria were subjects 18-75 years old who reported being generally healthy, with no history of diabetes, cardiovascular disease, renal disease, chronic lung disease or cancer. The median age of the participants was 36 years and 53% were female. Secretoneurin was measured in duplicate using an ELISA (CardiNor AS, Oslo, Norway).

The investigators reported that non-fasting glucose, eGFR (CKD-EPI), cardiac troponin T (cTnT), and brain natriuretic peptide (NT-proBNP) concentrations were within the normal range for the volunteers. Median secretoneurin concentrations for females were 35 pmol/L and for males 33 pmol/L, (P-value < 0.001). CVI and CVG were 9.8% (CI 8.7% - 11.0%) and 20.0 (CI 15.4% - 28.0%), respectively. RCV were 38.7% (CI 35.5% to 42.7%) and -27.9 (CI -29.9 to -26.2) and the II were 0.60 (CI 0.42 -0.78). No gender differences were found.

The authors concluded that this study is the first to report biological variation, RCV, II and analytical quality specifications for secretoneurin. Overall low values were found indicating that secretoneurin has characteristics suitable for a biomarker that could be useful for diagnosing and monitoring disease. The study was published on October 6, 2021 in the journal Clinical Biochemistry.

Related Links:
Haukeland University Hospital
CardiNor AS